Retatrutide, a innovative dual-acting glucose-dependent incretin mimetic, represents a significant leap in peptide treatments for the handling of type 2 sugar disorders and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor agonist and a GIP receptor stimulant, offering a m